The src family kinase inhibitors PP2 and PP1 block TGF-beta1- mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors

Current Cancer Drug Targets

Volumn 11, Issue 4, 2011, Pages 524-535

  Ungefroren, H ^a,b   Sebens, S ^a,c   Groth, S ^a,b   Gieseler, F ^b   Fandrich F ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

P38 MAPK; PP1; PP2; SB431542; Smad; Src; SU6656; TGF beta

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; BETA ACTIN; BIGLYCAN; CYCLIN DEPENDENT KINASE INHIBITOR 1; MITOGEN ACTIVATED PROTEIN KINASE P38; MUTANT PROTEIN; NERVE CELL ADHESION MOLECULE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT RECEPTOR; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENCY; DRUG RECEPTOR BINDING; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; METASTASIS; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; UPREGULATION;

BENZAMIDES; CADHERINS; CELL GROWTH PROCESSES; CELL LINE; CELL LINE, TUMOR; DIOXOLES; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; INDOLES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; PYRIMIDINES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SMAD2 PROTEIN; SRC-FAMILY KINASES; SULFONAMIDES; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79955584688     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911795538075     Document Type: Article

References (53)

1. Moustakas, A.; Pardali, K.; Gaal, A.; Heldin, C. H. Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol. Lett. 2002, 82, 85-91.
2. Derynck, R.; Zhang, Y. E. Smad-dependent and Smad-independent pathways in TGF-βββfamily signalling. Nature 2003, 425, 577-584.
3. Massagué, J.; Blain, S. W.; Lo, R. S. TGF βββsignaling in growth control, cancer, and heritable disorders. Cell 2000, 103, 295-309.
4. Bierie, B.; Moses, H. L. Tumour microenvironment: TGF β: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 2006, 6, 506-520.
5. Philip, P. A.; Mooney, M.; Jaffe, D.; Eckhardt, G.; Moore, M.; Meropol, N.; Emens, L.; O'Reilly, E.; Korc, M.; Ellis, L.; Benedetti, J.; Rothenberg, M.; Willett, C.; Tempero, M.; Lowy, A.; Abbruzzese, J.; Simeone, D.; Hingorani, S.; Berlin, J.; Tepper, J. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J. Clin. Oncol. 2009, 27, 5660-5669.
6. Bardeesy, N.; Cheng, K. H.; Berger, J. H., Chu, G. C.; Pahler, J.; Olson, P.; Hezel, A. F.; Horner J.; Lauwers, G. Y.; Hanahan, D.; DePinho, R. A. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006, 20, 3130-3146.
7. Ijichi, H.; Chytil, A.; Gorska, A. E.; Aakre, M. E.; Fujitani, Y.; Fujitani, S.; Wright, C. V.; Moses, H. L. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev. 2006, 20, 3147-3160.
8. Friess, H.; Yamanaka, Y.; Büchler, M.; Ebert, M.; Beger, H. G.; Gold, L. I.; Korc, M. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993, 105, 1846-1856.
9. Geismann, C.; Morscheck, M.; Koch, D.; Bergmann, F.; Ungefroren, H.; Arlt, A.; Tsao, M. S.; Bachem, M. G.; Altevogt, P.; Sipos, B.; Fölsch, U. R.; Schäfer, H.; Sebens Müerköster, S. Upregulation of L1CAM in pancreatic duct cells is transforming growth factor beta1-and slug-dependent: role in malignant transformation of pancreatic cancer. Cancer Res. 2009, 69, 4517-45426.
10. Schniewind, B.; Groth, S.; Sebens Müerköster, S.; Sipos, B.; Schäfer, H.; Kalthoff, H.; Fändrich, F.; Ungefroren, H. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function. Oncogene 2007, 26, 4850-4862.
11. Rowland-Goldsmith, M. A.; Maruyama, H.; Matsuda, K.; Idezawa, T.; Ralli, M.; Ralli, S.; Korc, M. Soluble type II transforming growth factor-beta receptor attenuates expression of metastasisassociated genes and suppresses pancreatic cancer cell metastasis. Mol. Cancer Ther. 2002, 1, 161-167.
12. Lutz, M. P.; Esser, I. B.; Flossmann-Kast, B. B.; Vogelmann, R.; Luhrs, H.; Friess, H.; Buchler, M. W.; Adler G. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem. Biophys. Res. Commun. 1998, 243, 503-508.
13. Menke, A.; Philippi, C.; Vogelmann, R.; Seidel, B.; Lutz, M. P.; Adler, G.; Wedlich, D. Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Res. 2001, 61, 3508-3517.
14. Trevino, J. G.; Summy, J. M.; Gray, M. J.; Nilsson, M. B.; Lesslie, D. P.; Baker, C. H.; Gallick, G. E. Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Res. 2005, 65, 7214-7222.
15. Ito, H.; Gardner-Thorpe, J.; Zinner, M. J.; Ashley, S. W.; Whang, E. E. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 2003, 134, 221-226.
16. Yezhelyev, M. V.; Koehl, G.; Guba, M.; Brabletz, T.; Jauch, K. W.; Ryan, A.; Barge, A.; Green, T.; Fennell, M.; Bruns, C. J. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin. Cancer Res. 2004, 10, 8028-8036.
17. Galliher, A. J.; Schiemann, W. P. Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelialmesenchymal transition in mammary epithelial cells. Breast Cancer Res. 2006, 8, R42.
18. Wang, S. E.; Xiang, B.; Zent, R.; Quaranta, V.; Pozzi A; Arteaga, C. L. Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. Cancer Res. 2009, 69, 475-482.
19. Kim, L. C.; Song, L.; Haura, E. B. Src family kinases as therapeutic targets for cancer. Nat. Rev. Clin. Oncol. 2009, 6, 587-595.
20. Melisi, D.; Ishiyama, S.; Sclabas, G. M.; Fleming, J. B.; Xia, Q.; Tortora, G.; Abbruzzese, J. L.; Chiao, P. J. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol. Cancer Ther. 2008, 7, 829-840.
21. Medicherla, S.; Li, L.; Ma, J. Y.; Kapoun, A. M.; Gaspar, N. J.; Liu, Y. W.; Mangadu, R.; O'Young, G.; Protter, A. A.; Schreiner, G. F.; Wong, D. H.; Higgins, L. S. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment. Anticancer Res. 2007, 27, 4149-4157.
22. Schlingensiepen, K. H.; Fischer-Blass, B.; Schmaus, S.; Ludwig, S. Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res. 2008, 177, 137-150.
23. Nagaraj, N. S.; Datta, P. K. Targeting the transforming growth factor-βββsignaling pathway in human cancer. Expert Opin. Investig. Drugs 2010, 19, 77-91.
24. Inman, G. J.; Nicolas, F. J.; Callahan, J. F.; Harling, J. D.; Gaster, L. M.; Reith, A. D.; Laping, N. J., Hill, C. S. SB-431542 is a potent and specific inhibitor of transforming growth factor-βββsuperfamily type I receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 2002, 62, 65-74.
25. Donnini, S.; Monti, M.; Castagnini, C.; Solito, R.; Botta, M.; Schenone, S.; Giachetti, A.; Ziche, M. Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling. Int. J. Cancer 2007, 120, 995-1004.
26. Hirokawa, Y.; Levitzki, A.; Lessene, G.; Baell, J.; Xiao, Y.; Zhu, H.; Maruta, H. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors). Cancer Lett. 2007, 245, 242-251.
27. Duxbury, M. S.; Ito, H.; Zinner, M. J.; Ashley, S. W.; Whang, E. E. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 2004, 10, 2307-2318.
28. Bain, J.; McLauchlan, H.; Elliott, M.; Cohen, P. The specificities of protein kinase inhibitors: an update. Biochem. J. 2003, 371, 199-204.
29. Maeda, M.; Shintani, Y.; Wheelock, M. J.; Johnson, K. R. Src activation is not necessary for Transforming growth factor (TGF)-β-mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. PP1 directly inhibits TGF-beta receptors I and II. J. Biol. Chem. 2006, 281, 59-68.
30. Eyers, P. A.; Craxton, M.; Morrice, N.; Cohen, P.; Goedert, M. Conversion of SB 203580-insensitive MAP kinase members to drug-sensitive forms by a single amino-acid substitution. Chem. Biol. 1998, 5, 321-328.
31. Nicolás, F. J.; Hill, C. S. Attenuation of the TGF-beta-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-beta-induced growth arrest. Oncogene 2003, 22, 3698-3711.
32. Fensterer, H.; Giehl, K.; Buchholz, M.; Ellenrieder, V.; Buck, A.; Kestler, H. A.; Adler, G.; Gierschik, P.; Gress, T. M. Expression profiling of the influence of RAS mutants on the TGFB1-induced phenotype of the pancreatic cancer cell line PANC-1. Genes Chromosomes Cancer 2004, 39, 224-235.
33. Kornmann, M.; Tangvoranuntakul, P.; Korc, M. TGF-beta-1 upregulates cyclin D1 expression in COLO-357 cells, whereas suppression of cyclin D1 levels is associated with down-regulation of the type I TGF-beta receptor. Int. J. Cancer 1999, 83, 247-254.
34. Chen, W. B.; Lenschow, W.; Tiede, K.; Fischer, J. W.; Kalthoff, H.; Ungefroren, H. Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells. J. Biol. Chem. 2002, 277, 36118-36128.
35. Ungefroren, H.; Lenschow, W.; Chen, W. B.; Faendrich, F.; Kalthoff, H. Regulation of biglycan gene expression by transforming growth factor-βββrequires MKK6-p38 mitogenactivated protein kinase signaling downstream of Smad signaling. J. Biol. Chem. 2003, 278, 11041-11049.
36. Groth, S.; Schulze, M.; Kalthoff, H.; Fändrich, F.; Ungefroren, H. Adhesion and Rac1-dependent regulation of biglycan gene expression by transforming growth factor-beta. Evidence for oxidative signaling through NADPH oxidase. J. Biol. Chem. 2005, 280, 33190-33199.
37. Voss, M.; Wolff, B.; Savitskaia, N.; Ungefroren, H.; Deppert, W.; Schmiegel, W., Kalthoff, H.; Naumann, M. TGFbeta-induced growth inhibition involves cell cycle inhibitor p21 and pRb independent from p15 expression. Int. J. Oncol. 1999, 14, 93-101.
38. Nam, J. S.; Ino, Y.; Sakamoto, M.; Hirohashi, S. Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin. Cancer Res. 2002, 8, 2430-2436.
39. Blake, R. A.; Broome, M. A.; Liu, X.; Wu, J.; Gishizky, M.; Sun, L.; Courtneidge, S. A. SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling. Mol. Cell. Biol. 2000, 20, 9018-9027.
40. Grau, A. M.; Zhang, L.; Wang, W.; Ruan, S.; Evans, D. B.; Abbruzzese, J. L.; Zhang, W.; Chiao, P. J. Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res. 1997, 57, 3929-3934.
41. Ijichi, H.; Otsuka, M.; Tateishi, K.; Ikenoue, T.; Kawakami, T.; Kanai, F.; Arakawa, Y.; Seki, N.; Shimizu, K.; Miyazono, K.; Kawabe, T.; Omata, M. Smad4-independent regulation of p21/WAF1 by transforming growth factor-beta. Oncogene 2004, 23, 1043-1051.
42. Ellenrieder, V.; Hendler, S. F.; Boeck, W.; Seufferlein, T.; Menke, A.; Ruhland, C.; Adler, G.; Gress, T. M. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res. 2001, 61, 4222-4228.
43. Ellenrieder, V.; Hendler, S. F.; Ruhland, C.; Boeck, W.; Adler, G., Gress, T. M. TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int. J. Cancer 2001, 93, 204-211.
44. Takekawa, M.; Tatebayashi, K.; Itoh, F.; Adachi, M.; Imai, K.; Saito, H. Smad-dependent GADD45beta expression mediates delayed activation of p38 MAP kinase by TGF-beta. EMBO J. 2002, 21, 6473-6482.
45. Wieser, R.; Wrana, J. L.; Massagué. J. GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex. EMBO J. 1995, 14, 2199-2208.
46. Ischenko, I.; Camaj, P.; Seeliger, H.; Kleespies, A.; Guba, M.; De Toni, E. N.; Schwarz, B., Graeb, C.; Eichhorn, M. E.; Jauch, K. W.; Bruns, C. J. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling. Oncogene 2008, 27, 7212-7222.
47. Trevino, J. G.; Summy, J. M.; Lesslie, D. P.; Parikh, N. U.; Hong, D. S.; Lee, F. Y.; Donato, N. J.; Abbruzzese, J. L.; Baker, C. H.; Gallick, G. E. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am. J. Pathol. 2006, 168, 962-972.
48. Gupta, S.; El-Rayes, B. F. Small molecule tyrosine kinase inhibitors in pancreatic cancer. Biologics 2008, 2, 707-715.
49. Summy, J. M.; Trevino, J. G.; Lesslie, D. P.; Baker, C. H.; Shakespeare, W. C.; Wang, Y.; Sundaramoorthi, R.; Metcalf, C. A. 3rd; Keats, J. A.; Sawyer, T. K.; Gallick, G. E. AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol. Cancer Ther. 2005, 4, 1900-1911.
50. Baker, C. H.; Trevino, J. G.; Summy, J. M.; Zhang, F.; Caron, A.; Nesbit, M.; Gallick, G. E.; Fidler, I. J. Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice. Int. J. Oncol. 2006, 29, 125-138.
51. Gaspar, N. J.; Li, L.; Kapoun, A. M.; Medicherla, S.; Reddy, M.; Li, G.; O'Young, G.; Quon, D.; Henson, M.; Damm, D. L.; Muiru, G. T.; Murphy, A.; Higgins, L. S.; Chakravarty, S.; Wong, D. H. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness. Mol. Pharmacol. 2007, 72, 152-161.
52. Bakin, A. V.; Rinehart, C.; Tomlinson, A. K.; Arteaga, C. L. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. J. Cell Sci. 2002, 115, 3193-3206.
53. Summy, J. M.; Trevino, J. G.; Baker, C. H.; Gallick, G. E. c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. Pancreas 2005, 31, 263-274.